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Abstract. Paragangliomas (carotid body 
turnouts, chemodectomas) may arise in any 
area of the body where sympathetic ganglia 
are present, including chemoreceptors, the 
adrenal medulla and retroperitoneal gang- 
lia. Increasing numbers of patients are 
being reported with vertebral metastases 
and spinal cord compression for which 
either decompression laminectomy or 
external beam radiotherapy, or both, are 
required. Patients with vertebral metas- 
tases may develop progression of disease 
after radiation therapy. 
There is little published information on 
the use of chemotherapy in this clinical 
situation. We report a case of metastatic 
paraganglioma complicated by spinal cord 
compression showing evidence of clinical 
benefit from chemotherapy after pro- 
gressive disease and symptoms developed 
in a region previously treated by radiation 
therapy. 
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INTRODUCTION 
Paragangliomas are uncommon tumours 
with a low propensity to metastasize. 
Recurrences or metastases may occur long 
after initial diagnosis, occasionally up to 20 
years [1]. Metastases to vertebrae, with or 
without extradural extension, are rare, with 
single cases constituting the reported litera- 
ture [1-8]. 
External beam radiotherapy is effective 
in the treatment of bony metastases [8] as 
well as primary paragangliomas [9], with 
local control and excellent pain relief in a 
high proportion of cases. However, many 
patients studied did not have prolonged 
follow-up and progression may occur years 
after therapy. Decompression laminectomy 
may be complicated by bleeding from these 
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vascular tumours [7], and multiple level 
laminectomy may result in vertebral 
instability. 
For patients with previously irradiated 
epidural disease who suffer pain or neuro- 
logical symptoms despite surgery, or who 
are unable to undergo surgery, systemic 
chemotherapy may offer an alternative. We 
report a case of metastastic paraganglioma 
demonstrating tumour regression after 
chemotherapy in an area previously treated 
by external beam radiation. 
CASE REPORT 
In December 1980 a 23-year-old man devel- 
oped symptoms o?f a flu-like illness. On 
physical examination an abdominal mass 
was found, confirmed by ultrasound and 
measuring 7 x 9 x 4 cm, lying to the right of 
the mid-line at the level of the umbilicus. At 
laparotomy a large retroperitoneal mass, 
extending from the renal arteries to the 
bifurcation of the aorta, was removed. 
Histological evaluation revealed a non- 
chromaffin paraganglioma (Figs. 1, 2). The 
patient had had no history of hypertension 
or headaches, and assays for catechola- 
mines were normal. 
He was well until April 1986 when he 
developed back pain. A bone scan revealed 
increased uptake at the ninth thoracic 
vertebra, as well as the sacrum. Computed 
tomography (CT) of the pelvis revealed a 
Fig. 1. Photomicrograph of original retroperito- 
nea/ tumour, illustrating uniform tumour cells 
arranged in nests ('Zellballen') separated by a 
prominent fibrovascular stroma (haematoxylin 
and eosin stain, original magnification x400). 
Fig. 2. Immunohistochemical stains demonstrat- 
ing intense positive reactivity for neuron specific 
enolase (A) and chromogranin (B) (ABC- 
peroxidase stain, original magnification x400). 
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large destructive lesion involving the 
sacrum, with an intrapelvic soft tissue com- 
ponent. A CT scan of T9 revealed 
destruction of the right side of this vertebral 
body with prominence of the adjacent para- 
vertebral soft tissue. Open biopsy of the 
pelvic mass and a needle biopsy of T9 
confirmed a diagnosis of paraganglioma. 
He subsequently received radiotherapy to 
the sacrum (total dose 5000 cGy in 25 
fractions) and to the lower thoracic verte- 
brae (total dose 4000 cGy in 20 fractions). 
He was again well until November 1988 
whe he developed back and neck pain and a 
right C7 and C8 radiculopathy. Myelo- 
graphy revealed impingement by epidural 
extension of tumour of the C7 and C8 roots. 
He received radiotherapy (3000 cGy in 10 
fractions) to the cervical vertebrae, Scan- 
ning with 131I-MIBG did not reveal signifi- 
cant radioisotopic uptake. 
In March 1989 he developed increasing 
pain at the level of Tg, and Lhermitte's sign 
on forward neck flexion, as well as an 
episode of loss of leg control. On examin- 
ation there was no evidence of spinal cord 
compression. A CT scan of the mid and 
lower thoracic vertebrae was performed 
(Fig. 3). Decompression laminectomy was 
suggested but the patient, concerned by the 
risk of back instability, declined. Chemo- 
therapy (cyclophosphamide 750 mg/m 2 and 
vincristine 2 mg/m 2 given on day 1, and 
dacarbazine (DTIC) 600 mg on days 1 and 2 
of a 28-day cycle) was commenced. After 
two courses the patient's pain (incom- 
pletely controlled on hydromorphone 6 mg 
every 4 hours) resolved, as did the Lher- 
mitte's sign. A C T  scan revealed a decrease 
in the paraspinal soft tissue mass (Fig. 4). 
Another CT scan obtained 2 months later 
revealed no further change. 
As the patient suffered considerable 
nausea with this regimen, he was subse- 
quently treated with carboplatin 300 mg/m 2 
every 28 days. A C T  scan obtained after 
two courses revealed further shrinkage of 
the soft tissue mass (Fig. 5), but no further 
shrinkage was achieved after two additional 
courses of carboplatin. 
Thirteen months after completion of 
chemotherapy the patient developed 
further pain in the lower thoracic region 
and weakness on climbing stairs. CT scan- 
ning revealed progression of the soft tissue 
lesion and obliteration of the spinal canal at 
T9 and T10. Surgery was reconsidered but 
the risk of back instability was felt to be 
high. The patient commenced dexametha- 
Fig. 3. CT scan through T9 vertebra revealing 
destructive lyric lesion of the body of the vertebra 
as well as paraspinal soft tumour extension. The 
epidural fat surrounding the spinal cord is dis- 
placed to the left and posteriorly. 
Fig. 4. CT scan of T9 vertebra after two courses 
of chemotherapy with cyclophosphamide, vin- 
cristine and dacarbazine. A noticeable decrease in 
the paraspinal mass is seen. 
Fig. 5. CT scan through T9 vertebra after two 
further courses of chemotherapy with carbo- 
platin. Still further shrinkage of the paraspinal 
mass is seen. The epidural fat surrounding the 
spinal cord is now well centred in the spinal canal, 
suggesting that the spinal cord is no longer 
displaced posteriorly. 
sone and accepted treatment with cisplatin 
(25 mg/m z intervenously daily for 3 days) 
and etoposide (100 mg/m ~ intravenously 
daily for 3 days). Within 1 week the 
patient's leg weakness and back pain had 
resolved, but he experienced substantial 
fatigue, and further chemotherapy was 
declined. 
The patient's pain recurred 4 weeks later, 
and decompression laminectomy was 
performed. Extensive bleeding resulted in 
abandonment of the planned anterior 
decompression. Although the canal 
appeared well decompressed by posterior 
laminectomy, the patient continued to lose 
function in his legs, and declined further 
intervention. He died 2 months later as a 
result of a pulmonary embolus; autopsy 
revealed two small deposits in the body of 
the pancreas as the only metastases outside 
the skeleton. 
DISCUSSION 
Little information is available on the 
chemotherapy of paraganglioma. Case 
reports of response to carboplatin (one 
partial [101 and one minor [11] response) 
have been published. Shepard et al. [12] 
reported a case achieving a complete re- 
sponse of pulmonary metastases and 
healing of lytic lesions with combination 
cisplatin and etoposide, despite prior pro- 
gressive disease with cyclophosphamide, 
doxorubicin and cisplatin, but with sub- 
sequent progression despite single agent 
etoposide. Vogl,et al. [13] reported a partial 
response in a patient treated with doxo- 
rubicin and cisplatin and Mikhail et al. [5] 
reported a case of partial response to 
cyclophosphamide, doxorubicin, vincris- 
tine and dacarbazine (CYVADIC). In con- 
trast, Poster et al. [14] and Massey and 
Wallner [8] treated patients with metastatic 
disease with various chemotherapy regi- 
mens, without evidence of response. 
The present case demonstrates both 
measureable regression of evaluable dis- 
ease and palliation of pain and other neuro- 
logical symptoms at a previously irradiated 
site through the use of cytotoxic chemother- 
apy. Turnout shrinkage was documented 
for cyclophosphamide, vincristine and 
dacarbazine, with a suggestion of further 
improvement with the subsequent adminis- 
tration of carboplatin (dose reduced as a 
result of previous myelosuppression). 
When signs and symptoms of spinal cord 
compression recurred, a combination of 
etoposide and cisplatin was commenced, 
but the transient symptomatic improve- 
ment may well have been due to cortico- 
steroid therapy. 
Standard therapy for spinal cord com- 
pression includes external beam radiother- 
apy with or without surgical decompression 
[15]. However, the long natural history of 
this disease may result in a recurrence of 
symptoms at previously treated sites. This 
report suggests that chemotherapy, 
although a far from optimal therapy in this 
clinical situation, may induce response and 
symptomatic improvement at metastatic 
sites despite previous radiotherapy. Based 
on response rates obtained in phaeo- 
chromocytoma [16], cyclophosphamide, 
vincristine and daearbazine should be 
considered for initial therapy, with other 
regimens, including single agent carbo- 
platin, reserved for patients who develop 
intolerable toxicity or fail to respond to the 
initial regimen. 
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Assessment of Visual Function for Patients 
on Tamoxifen 
SIR - A recent  issue of the Drug and 
Therapeutics Bulletin [1] reviewed the pro- 
cess of  follow-up in patients with a diagnosis 
of  breast cancer. One  of  the justifications 
given for following patients in clinics was 
the  moni tor ing of the effects of adjuvant  
therapy,  including tamoxifen.  The  report  
ment ioned  the occurrence of rare ocular 
complications, including cataract and reti- 
nopathy,  and suggests that  visual acuity 
should be checked before t rea tment  and 
probably annually while on tamoxifen.  
I am not aware of many  depar tments  
that  do this routinely,  and indeed,  if visual 
function was to be properly assessed for 
every person on tamoxifen,  this would 
create an enormous  workload for the 
oncology follow-up clinics and for ophthal-  
mologists if these patients were referred 
for formal assessment.  
The  early reports of tamoxifen-associ- 
ated ret inopathy suggested that doses 
higher  than  those traditionally used in this 
country were to blame [2]. However ,  since 
then more  recent reports,  including a small 
prospective study published this year [3] 
suggest  that  long-term low dose tamoxifen 
can induce ocular toxicity, a l though this is 
not  a consistent finding [4]. In the majority,  
bu t  not  all, of the reported cases the ocular 
changes are reversible. 
I feel that this is one area of practice in 
which it would be very useful to have a 
consensus  opinion on the need for visual 
assessment ,  to define what would be 
regarded as acceptable practice in this 
country. I wonder  if others would wish to 
express their opinions through the corres- 
pondence  columns of Clinical Oncology. 
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